MAVACAMTEN
mavacamten 5 mg capsule, 28
MAVACAMTEN (14117B)
14117B
Body System:
Manner of administration:Oral
Restriction
Indication: Symptomatic obstructive hypertrophic cardiomyopathy
Treatment phase: Initial treatment (covering the first 12 weeks of therapy)
Restriction
Indication: Symptomatic obstructive hypertrophic cardiomyopathy
Treatment phase: First continuing treatment (until at least 6 months on optimal dose is achieved)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 2 | DPMQ: $2,323.63 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Camzyos | |||||